Literature DB >> 23180629

RUNX family: Regulation and diversification of roles through interacting proteins.

Linda Shyue Huey Chuang1, Kosei Ito, Yoshiaki Ito.   

Abstract

The Runt-related transcription factors (RUNX) belong to an ancient family of metazoan genes involved in developmental processes. Through multiple protein-interacting partners, RUNX proteins have been implicated in diverse signaling pathways and cellular processes. The frequent inactivation of RUNX genes in cancer indicates crucial roles for RUNX in tumor suppression. This review discusses the abilities of RUNX proteins, in particular RUNX3, to integrate oncogenic signals or environmental cues and to initiate appropriate tumor suppressive responses.
Copyright © 2012 UICC.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23180629     DOI： 10.1002/ijc.27964

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  92 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

2.  Activation of Mouse Tcrb: Uncoupling RUNX1 Function from Its Cooperative Binding with ETS1.

Authors:  Jiang-Yang Zhao; Oleg Osipovich; Olivia I Koues; Kinjal Majumder; Eugene M Oltz
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

3.  Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.

Authors:  Hiroshi Moro; Naoko Hattori; Yoshiaki Nakamura; Kana Kimura; Toshio Imai; Masahiro Maeda; Masakazu Yashiro; Toshikazu Ushijima
Journal:  Gastric Cancer       Date:  2019-09-25       Impact factor: 7.370

4.  Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Mo Shi; Zhou Wang; Xiang-Yan Liu; Dong Chen
Journal:  Med Oncol       Date:  2014-11-13       Impact factor: 3.064

Review 5.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

6.  FOXO1 is required for binding of PR on IRF4, novel transcriptional regulator of endometrial stromal decidualization.

Authors:  Yasmin M Vasquez; Erik C Mazur; Xilong Li; Ramakrishna Kommagani; Lichun Jiang; Rui Chen; Rainer B Lanz; Ertug Kovanci; William E Gibbons; Francesco J DeMayo
Journal:  Mol Endocrinol       Date:  2015-01-13

Review 7.  Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes.

Authors:  Masahiro Ono
Journal:  Immunology       Date:  2020-03-09       Impact factor: 7.397

8.  Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice.

Authors:  Yukiko Komeno; Ming Yan; Shinobu Matsuura; Kentson Lam; Miao-Chia Lo; Yi-Jou Huang; Daniel G Tenen; James R Downing; Dong-Er Zhang
Journal:  Blood       Date:  2014-04-25       Impact factor: 22.113

9.  Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Authors:  Anne L Carlton; Anuradha Illendula; Yan Gao; Danielle C Llaneza; Adam Boulton; Anant Shah; Roger A Rajewski; Charles N Landen; David Wotton; John H Bushweller
Journal:  Gynecol Oncol       Date:  2018-03-16       Impact factor: 5.482

10.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.